Agenda

 
 
 

 

Online - LIVE, 8 - 9 October 2020

Schedule

Create your personal agenda –check the favourite icon

Oct 808:20
Conference pass

Conference Organizer Opening Remarks

Keynotes
Opening remarks will be given by Claire Murphy, Production Director, World AMR Congress
Oct 808:25
Conference pass

Chairperson Opening Remarks

Keynotes
Erin Duffy, Chief Of Research And Development, CARB-X
Oct 808:30
Conference pass

Innovating to secure the future, investing for a sustainable response: bringing together the science, policy and economics to tackle AMR today and in the future, for the future of modern medicine

Keynotes
Professor Dame Sally Davies, Special Envoy on AMR, UK Government
Oct 809:00
Conference pass

Remarks & Q&A: The Future of AMR in the U.S. Congress: US Senator Michael Bennet will discuss the latest work being done to address antimicrobial resistance in the United States Congress, including hi

Keynotes
Moderator: Kevin Outterson, Executive Director, CARB-X
Michael Bennet, Senator, (D-Colo.), United States Senate
Oct 809:00
Conference pass

BH01, an Engineered Peptide Lysin for the treatment of Carbapenem Resistant Acinetobacter Infections

On-Demand
Chandrabali Ghose, Founder And Chief Executive Officer, Bioharmony Therapeutics
Oct 809:25
Conference pass

Fireside Chat: AMR Action Fund

Keynotes
Description to be announced
Erin Duffy, Chief Of Research And Development, CARB-X
Thomas Cueni, General Director, International Federation of Pharmaceutical Manufacturers and Associations
Oct 810:00
Conference pass

Panel & Audience Q&A: Supporting access and innovation through antibiotic reimbursement reform

Keynotes
-Overview and importance of DISARM Act-Multi-stakeholder perspective on current reimbursement reform efforts – challenges and opportunities-Impact of COVID-19, AMR Action Fund, and ex-US initiatives
Moderator: Amanda Jezek, Senior Vice President, Public Policy And Government Relations, Infectious Diseases Society of America
Greg Frank, Director, Infectious Disease Policy, BIO
Helen Boucher, Chief, Division of Geographic Medicine, Infectious Diseases, Director, Tufts Center for Integrated Management of Ant Resistance, Tufts Medical Center
Silas Holland, Head of External Affairs, Merck
Jeremy Knox, Jeremy Knox, Director Of Policy, Drug Resistant Infections, Wellcome Trust
Oct 810:50
Conference pass

10:50 BREAK

Keynotes
Networking Break
Oct 811:00
Conference pass

One Health for All: U.S. Strategies to Collaborate and Combat Antibiotic-Resistance

One Health
Jomana Musmar, Designated Federal Officer, Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, DHHS
Oct 811:00
Conference pass

Synthetic Antibiotics: The New Approach the World Needs

Antibiotic R&D
Michele Dilizia, Vice President Regulatory Affairs and Microbiology, Co-inventor of RECCE antibiotics, Recce Pharmaceuticals
Oct 811:00
Conference pass

Kill Switch: A Critical Tool in the Fight Against AMR

Innovation Showcase
Ravi Starzl, Co-Founder And Chief Executive Officer, BioPlx, Inc.
Oct 811:20
Conference pass

Session title to be announced

Antibiotic R&D
Marina Kozak, Project Officer, BARDA
Oct 811:20
Conference pass

PANEL: Funding and Partnering landscape for non-traditional approaches for treating resistant infections and combatting AMR

Innovation Showcase
Moderator: Richard Alm, Alliance Director, CARB-X
Carrie-Lynn Langlais Furr, CEO and Cofounder, Bacteriophage & Drug Development Consultants
Christopher Tan, Director, Business Development And Licensing, Search And Evaluation, Infectious Diseases And Vaccines, Merck
Vijay Dahiya, Head of Business Development and Licensing, Cipla
Oct 812:10
Conference pass

Development of Phage Therapeutics Targeting Pseudomonas aeruginosa and Staphylococcus aureus

Innovation Showcase
Brian Varnum, President and Chief Development Officer, Armata Pharmaceuticals
Oct 812:30
Conference pass

Session title to be announced

Innovation Showcase
Thierry Bernardi, Chief Executive Officer, Biofilm Pharma
Oct 812:50
Conference pass

Pets, manure and AMR

One Health
Laura Kahn, Co-Founder, One Health Initiative
Oct 812:50
Conference pass

The use of Synthetic Bacteriophages and Their Advantages over Naturally-Found Bacteriophage

Innovation Showcase
Steven Theriault, Scientist, Professor, CEO & CSO, Cytophage Technologies Inc.
Oct 813:10
Conference pass

Entering a new platinum age of antibiotic discovery by forming strategic & innovative partnerships

Keynotes
The "sun is setting" on the golden age of antibiotics where the strategy of derivatizing old chemical scaffolds to overcome drug resistance, has run its course. The "dawn is rising" on a new age, called the Platinum Age, one that will be characterized by novel classes of antibiotics (novel MoAs and targets), personalized health care solutions for patients with drug-resistant infections, and new business models for a sustainable antibiotics ecosystem. These ideas will be discussed during this session.
Zak Zimmerman, Chief Executive Officer, Forge Therapeutics
John Young, Global Head Infectious Diseases, Roche
Oct 814:10
Conference pass

Roundtable 1: Partnering with Nurses – Importance of Nurse Participation in Antimicrobial Stewardship Programs

Keynotes
Geneen Gibson, Coordinator, Antimicrobial Management Program, St. Joseph's/Candler Health System, Inc.
Rita Olans, Assistant Professor, School Of Nursing, MGH Institute of Health Professions
Oct 814:10
Conference pass

Roundtable 2: Patient Groups & AMR – the role of the patient groups to generate public awareness and support AMR ecosystem

Keynotes
Mary Millard, Patient Advocate, Sepsis Survivor
Armando Nahum, Patient Advocate, Voting Memeber, PACCARB, Director,, Center for Engaging Patients as Partners
Christian Lillis, Executive Director, Peggy Lillis Foundation
Oct 814:10
Conference pass

Roundtable 3: Microbiome Development

Keynotes
Session details to be announced
Oct 814:10
Conference pass

Roundtable 4: COVID-19 & infection control - considerations for infection control practices in the COVID-19 pandemic

Keynotes
Taylor Mcllquham, Infection Control Epidemiologist, Johns Hopkins Medicine
Oct 815:15
Conference pass

Session title to be announced

Antibiotic R&D
César De La Fuente, Presidential Assistant Professor At Upenn And Leader, Machine Biology Group, University of Pennsylvania
Oct 815:15
Conference pass

Case study: Showing ROI of a rapid DX in the hospital setting

Diagnostics
Katherine K Perez, Infectious Diseases Clinical Specialist, Houston Methodist Hospital
Oct 815:15
Conference pass

Update on US-China policy for supply chain and manufacturing of antibiotics & API’s

Manufacturing
Allan Coukell, Senior Vice President, Public Policy, Civica Rx
Oct 815:35
Conference pass

Supporting antifungal development using molecular technology and characterizing resistance genes

Antibiotic R&D
Mariana Castanheira, Chief Scientific Officer, JMI Laboratories
Oct 815:35
Conference pass

Session to be announced

Diagnostics
Sponsored by Biofilm Pharma
Oct 815:35
Conference pass

Managing AMR risks across Antibiotic supply chains

Manufacturing
Speaker to be announced soon.
Moderator: Steve Brooks, Advisor, AMR Industry Alliance
Nicolai Schaaf, Programme Manager, SIWI - Stockholm International Water Institute
Alistair Boxall, Professor, University of York Institute
Oct 815:55
Conference pass

PANEL: Reimbursement for diagnostics - incentivizing wider use of diagnostics to gather better surveillance data of antibiotic prescribing

Diagnostics
Speaker information to be announced soon
Oct 815:55
Conference pass

Reimbursement for diagnostics - incentivizing wider use of diagnostics to gather better surveillance data of antibiotic prescribing

Diagnostics
Monika Schneider, Research Associate, Margolis Center For Health Policy, Duke University
Oct 816:40
Conference pass

Keynote: Role of Pharmacists in the management of new agents: supporting appropriate use and patient access to new agents

Keynotes
Jason Pogue, President - Elect, Society of Infectious Disease Pharmacists
Susan Davis, Clinical Professor, Pharmacy Practice, Wayne State University, Infectious Diseases Pharmacist, Henry Ford Hospital

Create your personal agenda –check the favourite icon

Oct 908:25
Conference pass

Opening remarks

Keynotes
Opening remarks will be given by Claire Murphy, Production Director, World AMR Congress
Oct 908:30
Conference pass

AMR is An Enduring Danger in the Age of the COVID-19 Pandemic: Every Stakeholder Must Work Towards a Solution

Keynotes
Julie Gerberding, Executive Vice President, Communications, Global Policy, And Population Health And Chief Patient Officer, Merck
Oct 908:55
Conference pass

A vision for a global public health response to AMR – what have we learned from COVID-19

Keynotes
Haileyesus Getahun, Director, Department of Global Coordination and Partnership (GCP) on Antimicrobial Resistance (AMR), World Health Organisation
Oct 909:20
Conference pass

Impact of COVID-19 on healthcare and resistance: examining secondary bacterial infections in both COVID-19 and the broader areas of medicine. What are the key takeaways for treatment, increased resist

Keynotes
Neil Clancy, Associate Professor Of Medicine, Infectious Diseases Division, And Director, Mycology Program, University of Pittsburgh
Oct 910:30
Conference pass

To Approval and Beyond: The Elements of Commercial Success in Today’s Challenging Antimicrobial Market

Antibiotic R&D
Evan Loh, Chairman, Antimicrobials Working Group, Chief Executive Officer, Paratek Pharmaceuticals , Inc.
Oct 910:30
Conference pass

Sponsored by Abbott: Evidence of the value of point of care testing to reduce inappropriate antibiotic use

Diagnostics
The session is sponsored by Abbott.
Jonathan Cooke, Honorary Professor, Pharmacy School, Visiting Professor in the Infectious Diseases, Immunity Section, Imperial College London, The University of Manchester
Oct 910:30
Conference pass

PANEL: Addressing the biggest challenges stewardship programs face in COVID-19 - what are the solutions and how are programs managing the tsunami of information

Stewardship
Moderator: Debbie Goff, Infectious Diseases Specialist, College Of Pharmacy, Ohio State University Medical Center
Erin Mccreary, Pharmacist, University of Pittsburgh Medical Center
Angeliki Messina, Head: Antimicrobial Stewardship,, Netcare, South Africa
Oct 910:50
Conference pass

Panel: How can we leveraging advancements from COVID-19 in diagnostics, data reporting and operations be applied to advance those areas in AMR

Diagnostics
-Case studies and point-of-care diagnostics-Improved data collection, IT and reporting
Charley John, Director, Us Public Policy, Walgreen Co.
Eric Wenzler, Assistant Professor, Department Of Pharmacy Practice, University of Maryland
Oct 910:50
Conference pass

How manufacturers can play a role in AMR - market access and international stewardship strategies

Commercial
Jaideep Gogtay, Chief Medical Officer, cipla
Oct 911:10
Conference pass

PANEL: How to successfully implement new CMS in-patient and out-patient stewardship requirements

Stewardship
Moderator: Debbie Goff, Infectious Diseases Specialist, College Of Pharmacy, Ohio State University Medical Center
Fatima Brakta, Pharmacy Clinical Manager, University Medical Center of New Orleans
Oct 911:30
Conference pass

Building a commercially sustainable antibiotic model

Antibiotic R&D
Cristina Larkin, Chief Operating Officer, Spero Therapeutics
Oct 912:00
Conference pass

Lunch Keynote: Pangenomic Microbial Memory: The Origin of the AMR Crisis

Keynotes
Ravi Starzl, Co-Founder And Chief Executive Officer, BioPlx, Inc.
Oct 912:40
Conference pass

Roundtable 1: Commercial model – exploring alternative partnering for ongoing manufacturing and sales of antibiotics to support financial sustainability of developers

Keynotes
Allan Coukell, Senior Vice President, Public Policy, Civica Rx
Oct 912:40
Conference pass

Roundtable 2: Strategic commercial options – evaluating a commercial path forward with a combination of policy, incentives, business development

Keynotes
Speaker information to be announced soon
Oct 912:40
Conference pass

Roundtable 3: Non-traditional regulatory development – Clarifying clinical pathways for non-traditional development

Keynotes
Speaker information will be available soon.
Oct 912:40
Conference pass

Roundtable 5: COVID-19 & national AMR strategies - agency perspectives on how to be prepared for an emergent resistant outbreak

Keynotes
Speaker to be announced
Oct 912:40
Conference pass

Roundtable 5: FDA Roundtable Discussion

Keynotes
Sumathi Nambiar, Director, Division Of Aniti-Infective Products, FDA
Oct 913:50
Conference pass

Update from FDA on diagnostic development

Diagnostics
Ribhi Shawar, Branch Chief, Division Of Microbiology, Cdrh Oivd, FDA
Oct 913:50
Conference pass

The Next Antibiotic Blockbuster: An Oxymoron or a Possibility?

Commercial
Rolf Wagenaar, executive director, AbbVie
Oct 913:50
Conference pass

PANEL: Sepsis versus stewardship and UCI considerations

Stewardship
Ed Septimus, Professor Internal Medicine, Texas A&M Health Science Center
Nikunj Vyas, Clinical Pharmacist, Infectious Diseases, Jefferson Health
Cindy Hou, Infection Control Officer, Jefferson Health
Thomas Heymann, Executive Director, Sepsis Alliance
Oct 914:10
Conference pass

Aligned by Design – Leveraging diagnostics to support appropriate use and development of therapeutics and preventatives

Diagnostics
  • Developing Dx/Tx Partnerships to support clinical trials
  • Resistance-Guided Therapy – How can diagnostics help preserve antibiotics
  • Diagnostic tests for non-traditional therapies
Moderator: Betsy Wonderly Trainor, Alliance Director, CARB-X
Oct 914:10
Conference pass

Commercial Perspective on New Product Launch

Commercial
Nathan McCutcheon, Executive Vice President and Chief Commercial Officer, Shionogi Inc
Oct 914:30
Conference pass

PANEL: Lessons learned from pre & post-launch

Commercial
  • Utility of health economic data
  • Influence of stewardship
  • Changes in the post-COVID world
  • Potential impact of reimbursement reform
Moderator: Larry Edwards, CEO, Tetraphase Pharmaceuticals
Michael Mcguire, Senior Vice President, Commercial, Melinta therapeutics
Rolf Wagenaar, executive director, AbbVie
Christine Ann Miller, President and Chief Executive Officer, Melinta therapeutics
Oct 914:40
Conference pass

PANEL: Hospital and industry collaboration: best practices for antibiotic stewardship for resistant pathogens

Stewardship
Moderator: Karri Sutter, Regional Medical Scientific Director, MERCK & CO., INC.
Matthew Goetz, Chief Of Infectious Diseases, V.A. Greater Los Angeles Healthcare System
Ryan Shields, Director of Antibiotic Management Program, University of Pittsburgh
Andrew Read, Director, Huck Institutes of the Life Sciences, Penn State University
Ravina Kullar, Antimicrobial Stewardship Pharmacist and Epidemiologist, Expert Stewardship
Oct 915:30
Conference pass

Impact of breakpoints on the commercialization and market access for new antimicrobials

Commercial
-Breaking down barriers on implementing updates to old breakpoints-Educating HCP on using newer agents in the meantime
Moderator: Kevin Krause, Vice President, Clinical Sciences & Development Operations, AN2 Therapeutics
Mariana Castanheira, Chief Scientific Officer, JMI Laboratories
Michael Dudley, President, CEO and Co-founder, Qpex Biopharma
Oct 915:30
Conference pass

PANEL: Vaccine development against resistant pathogens

Vaccines
Speaker information will be announced soon
Moderator: Ed Buurman, Alliance Director, CARB-X
Arne Van Bonin, Senior Director, Head of Biology Vaxxilon Unit, Idorsia Pharmaceuticals Ltd
Oct 915:30
Conference pass

Panel: Hospital infection control responses to COVID-19 - implications and lessons learned for resistance infections

Infection Control
Moderator: Linda Lybert, Founder And Executive Director, Healthcare Surfaces Institute
Angella Browne, Infection Contol Officer, Howard University Hospital
Marie Moss, Director, Infection Control, The Mount Sinai Hospital
Mark Moore, Infection Control Coordinator, John’s Hopkins Bayview Medical Center
Oct 915:50
Conference pass

Facilitating market access and penetration for antibiotics through Real World Evidence – feasibility and best practices with limited budgets

Commercial
Speaker to be announced soon
Oct 915:50
Conference pass

Value of vaccines in AMR: Making the case to external stakeholders and internal strategies for gaining public support

Vaccines
Speaker to be announced soon
last published: 25/Sep/20 15:35 GMT

DOWNLOAD PROSPECTUS

 

 


GET INVOLVED AT

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


Claire Murphy  

claire.murphy@terrapinn.com
+1 646.619.1784

 

 

Press & Media Partnerships

 


Molly Paprota
molly.paprota@terrapinn.com
+1 646.619.1815

 

 

To Speak

 


Claire Murphy
claire.murphy@terrapinn.com
+1 646.619.1784